天风证券（601162）发布研报称，预计时代天使(06699)2025-2027年营业收入分别为3.42/4.06/4.78亿美 元(2025/2026/2027年前值分别为3.22/3.83/4.53亿美元)，归母净利润分别为0.12/0.23/0.40亿美元 (2025/2026/2027年前值分别为0.12/0.21/0.38亿美元)，上调原因系全球化扩张提速，维持"买入"评级。8 月25日，公司发布2025年中报。2025年H1公司实现收入1.61亿美元，同比增长33.1%，归母净利润为 1464.30万美元，同比增长364.25%。经营性现金流为1753.50万美元，同比增长196.72%。 ...

Core Viewpoint - Tianfeng Securities has raised its revenue and net profit forecasts for Times Angel (06699) for the years 2025-2027, citing accelerated global expansion, and maintains a "Buy" rating [1] Financial Projections - Expected revenues for Times Angel are projected to be $342 million, $406 million, and $478 million for 2025, 2026, and 2027 respectively, up from previous estimates of $322 million, $383 million, and $453 million [1] - Forecasted net profits for the same years are $12 million, $23 million, and $40 million, adjusted from prior estimates of $12 million, $21 million, and $38 million [1] Recent Performance - For the first half of 2025, Times Angel reported revenues of $161 million, representing a year-on-year growth of 33.1% [1] - The net profit for the same period was $14.64 million, showing a significant year-on-year increase of 364.25% [1] - Operating cash flow for the first half of 2025 reached $17.54 million, reflecting a year-on-year growth of 196.72% [1]

Group 1 - Tianfeng Securities initiates coverage on Qianxin Biologics-B (02509) with a "Buy" rating, projecting revenue of RMB 3.22 billion, RMB 4.41 billion, and RMB 5.93 billion for 2025-2027 respectively, and sets a target price of RMB 36.85, equivalent to HKD 40.25 for 2025 [1] - The autoimmune disease biopharmaceutical market in China is expected to reach RMB 36.3 billion by 2024, with biologics' market share projected to increase to 65.6% by 2030. The psoriasis market is anticipated to reach RMB 30.65 billion by 2030, while the ankylosing spondylitis market is expected to reach approximately RMB 46.3 billion by 2030 [1] - Current first-line treatments for autoimmune diseases like psoriasis and ankylosing spondylitis primarily involve corticosteroids, immunosuppressants, and non-steroidal anti-inflammatory drugs, which have limitations such as short treatment duration and systemic side effects [1] Group 2 - The company has a robust pipeline in monoclonal antibodies for autoimmune diseases, with QX001S being the first approved biosimilar of ustekinumab in China, significantly improving accessibility for psoriasis treatment [2] - QX008N has completed Phase II enrollment for chronic obstructive pulmonary disease, leading the domestic market, while QX005N has received breakthrough therapy designation and completed Phase III enrollment for nodular prurigo [2] - QX002N has completed Phase III trials for ankylosing spondylitis, with a BLA submission expected in H2 2025, and QX004N has shown significant efficacy and safety for psoriasis, initiating Phase III trials [2] Group 3 - The company is advancing differentiated long-acting bispecific antibodies and actively pursuing overseas business development and licensing collaborations [3] - The rabbit antibody development platform enables high-activity antibody screening and early commercial feasibility assessments, focusing on key signaling pathways in autoimmune diseases [3] - The company has multiple bispecific antibody pipelines, including QX030N, which has completed its first overseas New Co transaction, and QX027N and QX035N, which are set for IND submissions in China and the U.S. [3] Group 4 - The company is diversifying its commercialization efforts through strategic partnerships, including collaborations with Huadong Medicine for QX001S and QX005N, and exclusive licensing agreements with Hansoh Pharmaceutical and Health元 for various products [4] - An exclusive licensing agreement has been signed with Caldera Therapeutics for the global development and commercialization of long-acting bispecific antibody QX030N [4]

公司兔抗体开发平台兼具高活性抗体筛选和早期商业可行性评估功能，并始终聚焦自免疾病信号通路上 下游核心靶点：(1)银屑病上游细胞因子IL12/IL-23p40与IL-23p19;(2)哮喘上游警报分子TSLP;(3)2型炎症 反应的上游受体IL-4Rα;(4)关键促炎效应分子IL-17A;(5)肥大细胞主要调节因子c-kit。 自身免疫性疾病生物药市场代开发潜力广阔 2024年中国自身免疫性疾病药物市场规模达363亿元，生物制剂占比逐年提升，预计2030年提升至 65.6%，其中：中国银屑病市场规模2030年预计达306.5亿元;2022年中国强直性脊柱炎患者人数为390万 人，预计到2030年市场规模达约463亿元。目前，银屑病与强直性脊柱炎等自身免疫性疾病的一线治疗 以糖皮质激素、免疫抑制剂和非甾体抗炎药为主，存在疗程持续性较短与全身性副作用等问题。 深度聚焦自免领域生物制剂研发，夯实公司研发与商业化基础 公司在自免单抗管线上有丰富的产品布局，其中，QX001S(IL-23p40)是国内首个获批的乌司奴单抗生物 类似药，可显著提高银屑病治疗的临床可及性;QX008N(TSLP)完成慢性阻塞性肺疾病II期入组 ...

Core Viewpoint - The overall white liquor industry is still in an adjustment period, leading to a downward revision of the profit forecast for Zhenjiu Lidu (06979) for 2025-2027 [1] Financial Performance - For H1 2025, the company reported revenue of 2.497 billion yuan, a year-on-year decrease of 39.6%, and a net profit of 575 million yuan, down 23.5% [1][2] - The expected revenue for 2025-2027 is revised to 5.978 billion, 6.590 billion, and 7.141 billion yuan, down from previous estimates of 7.328 billion, 8.100 billion, and 8.786 billion yuan [1][5] - The expected net profit for the same period is adjusted to 1.073 billion, 1.294 billion, and 1.700 billion yuan, compared to previous forecasts of 1.525 billion, 1.820 billion, and 2.305 billion yuan [1][5] Sales and Volume Analysis - The company's liquor business revenue for H1 2025 was 2.497 billion yuan, with a volume decrease of 35.58% to 9,125 tons and an average price drop of 6.20% to 273,700 yuan per ton [2] - Revenue by brand showed Zhenjiu, Lidu, Xiangjiao, and Kaikouxiao at 1.492 billion, 611 million, 277 million, and 81 million yuan respectively, with year-on-year declines of 44.80%, 9.40%, 38.73%, and 63.91% [2] Margin and Cost Analysis - The gross margin for H1 2025 improved by 0.28 percentage points to 59.04%, while the net profit margin increased by 4.83 percentage points to 23.02% [4] - The improvement in gross margin is attributed to a higher proportion of Lidu, which has a better margin, and the release of self-owned production capacity, reducing unit costs [4] Strategic Outlook - The company is focusing on mid-to-high-end products and expanding banquet scene channels to drive stable growth in 2025 [5] - The company maintains a "buy" rating despite the overall adjustment in the white liquor industry [1][5]

天风证券（601162）发布研报称，考虑当前白酒行业整体仍处于调整期，调低珍酒李渡(06979)2025- 2027年盈利预测，预计2025-2027年，公司实现营业收入59.78、65.90、71.41亿元(前值73.28、81.00、 87.86亿元)，实现归母净利润10.73、12.94、17.00亿元(前值15.25、18.20、23.05亿元)，对应PE(2025-09- 29收盘)为26.58、22.03、16.77X，维持"买入"评级。公司发布2025年中报。2025H1公司营业收入/净利 润/经调净利润分别为24.97/5.75/6.13亿元(同比-39.6%/-23.5%/-39.8%)。 自有产能释放贡献毛利率提升 25H1公司毛利率提升0.28pcts至59.04%，归母净利率提升4.83pcts至23.02%，销售费用率、管理费用率 分别+1.15/+3.34pcts至22.24%/9.76%。毛利率提升预计主要系：1、毛利率更高的李渡占比提升；2、自 有产能释放取代外购降低单位成本。 25年保持战略定力，多措并举促增长 25年公司顺应需求变化，产品侧重次高端&中端价位，渠道加大宴席场 ...

格隆汇9月30日｜A股券商股早盘低迷，其中，湘财股份跌超3%，中信证券、天风证券、华泰证券等个 股跟跌，国盛金控逆市上行走出两连板。 ...

凤凰网财经讯 9月30日，A股三大指数集体高开，沪指涨0.19%，深成指涨0.19%，创业板指涨0.04%。 工业金属、半导体等板块涨幅居前。 机构观点 华泰证券：重视优质银行股配置性机会 天风证券表示，商务部等八部门联合印发《关于大力发展数字消费共创数字时代美好生活的指导意 见》，聚焦供需双侧协同发力，重点看好AI终端设备产业链机遇。文件明确提出加速人工智能终端产 品创新，重点释放人工智能手机、电脑、可穿戴设备、智能机器人等新产品消费潜力，并推动智能家电 互联互通及智能网联汽车试点，以新供给激发新需求。该政策举措不仅将直接刺激数字消费市场，更将 形成"需求牵引供给"的良性循环，带动芯片、传感器等上游产业链升级，为消费电子产业注入新动能。 华泰证券表示，考虑风格均衡、日历效应与红利价值，银行配置性价比有所提升。受资金偏好切换影 响，7月中旬以来银行最大回撤约15%，部分优质银行25E股息率回到5%以上，随大盘上涨斜率放缓+经 济数据基数扰动，Q4资金或有避险需求，叠加年底日历效应，银行短期胜率有望改善。中期维度，政 策层面重视稳息差+预防尾部风险，银行核心业务盈利有望持续改善，资产质量担忧缓释，股息持续性 增 ...

Core Viewpoint - The joint issuance of guidelines by eight departments, including the Ministry of Commerce, aims to significantly boost digital consumption and create a better life in the digital age, with a focus on the AI terminal device industry chain opportunities [1] Group 1: Policy Initiatives - The guidelines emphasize accelerating innovation in artificial intelligence terminal products, particularly in areas such as AI smartphones, computers, wearable devices, and intelligent robots [1] - The initiative promotes the interconnectivity of smart home appliances and pilot projects for intelligent connected vehicles, aiming to stimulate new demand through new supply [1] Group 2: Market Impact - The policy measures are expected to directly stimulate the digital consumption market and create a virtuous cycle of "demand driving supply" [1] - This will lead to upgrades in upstream industries such as chips and sensors, injecting new momentum into the consumer electronics industry [1]

Core Viewpoint - Tianfeng Securities reports that planetary roller screws offer higher precision, longer lifespan, and greater load capacity, with potential applications in automotive steer-by-wire chassis systems [1] Application Areas - In the robotics sector, ball screws and planetary roller screws are predominant; in the automotive sector, ball screws are widely used in chassis, while planetary roller screws are emerging as a new technological direction [2] - In braking systems, the trend is moving from traditional hydraulic brakes to electro-hydraulic mixed brakes (EHB) and then to electromechanical brakes (EMB), with planetary roller screws gradually replacing existing technologies due to their low friction, high load capacity, and long lifespan [2] - In steering systems, rear-wheel steering technology (RWS) can control the rear wheel's steering angle, significantly enhancing vehicle handling; planetary roller screws may be used in this technology, offering advantages over current ball screws or belt drives [2] - In active suspension systems, planetary roller screws possess higher load capacity, longer lifespan, and more compact structure, indicating potential for increased application in electric suspension systems as performance requirements evolve [2] Competitive Landscape - The market is currently dominated by international leaders, with foreign manufacturers holding over 60% market share in 2022; Swiss company GSA/Rollvis leads with a 52% share [3]